DAs were widely used for the treatment of prolactinomas and some somatotropinomas, and the responsiveness depends on the expression of dopamine D2 receptors (D2R) on tumor cells. This evidence concerns the gene DRD2 and growth hormone-producing pituitary gland neoplasm.